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Abstract
Radioimmunotherapy (RIT) of Non-Hodgkin’s lymphoma (NHL) is said to be more 
advantageous compared to unlabelled therapeutic antibodies. To this date, radiolabelled murine 
anti-CD20 mAbs, Zevalin® and Bexxar® have been approved for imaging and therapy. A 
preparation containing rituximab, chimeric mAb radio immunoconjugate suitable for Lu-177 
labeling, could provide better imaging and therapeutic profile at the same time.  This study was 
conducted to evaluate prepared lyophilized formulations of two rituximab immune conjugates, 
intended for immediate Lu-177 labeling, for imaging and therapy.
The characterization of the conjugates and demonstration of the integrity of the protein and 
purity after conjugation and lyophilization was performed by SDS-PAGE, FT-IR and MALDI-
TOF-MS. The results showed preserved antibody structure and average of 6.1 p-SCN-Bn-
DOTA and 8.8 p-SCN-Bn-DTPA groups per antibody molecule which is suitable for successful 
labeling.  These results support the possibility of developing a “ready-to-label” rituximab 
immune conjugates for NHL imaging/therapy.
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Introduction
Non-Hodgkin’s lymphoma (NHL) is a form 
of blood cancer with origin in lymphatic system. 
More than 90% of B-cell lymphoma cells 
express CD20 receptor, but it is not expressed on 
cells in stem and progenitor cell pools.  CD20 has 
proven to be an excellent target for the treatment 
of B-cell lymphoma (1) and investigations 
for treatment of NHL have been based on 
the development of antibody against CD20 
antigens (2). Results of these investigations 
have led to drugs such as rituximab, a chimeric 
antibody for immunotherapy of CD20-
positive low-grade NHL, and ibritumomab and 
tositumomab, both murine antibodies, for the 
treatment of follicular lymphoma (3-5). Anti-
CD20 monoclonal antibodies (mAbs) labeled 
with 111In (111In-ibritumomab) for imaging, 90Y 
(90Y-ibritumomab, Zevalin) for therapy and 131I 
(131I-tositumomab, Bexxar) for imaging and 
therapy have been approved for use in patients 
with NHL (5-8). Radioimmunotherapy (RIT), 
is said to be more advantageous compared to 
unlabelled therapeutic antibodies, but RIT with 
murine antibodies often has limitations like 
development of human anti-mouse antibodies 
(HAMA) (9). To overcome these limitations, 
rituximab radioimmune conjugates are under 
investigation for RIT. Various radionuclides, 
among them 90Y (10, 11), 111In (10-12), 64Cu 
(13), 153Sm (14), 177Lu (9, 10, 15), attached to 
antibody through different chelating agents, 
have been described or are under development. 
A number of chelating agents have been 
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investigated for labeling proteins and peptides 
with radiometals, with various derivatives 
of the acyclic agent diethylene triamine 
pentaacetic acid (DTPA) and the macrocyclic 
agent 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid  (DOTA) being the most widely 
investigated (16).
Therapeutic monoclonal antibodies are 
very complex molecular structures that are 
joined together with weak, non-covalent or 
strong covalent, disulphide bonds, and their 
integrity is of exquisite importance for the 
physico-chemical stability and immunological 
potential. Proteins intended for therapy are often 
formulated in aqueous solution to allow ease of 
use, but it is known that aqueous environment 
can accelerate many degradation processes (17, 
18). Although instabilities can be found in solid 
state also, the common approach of stabilization 
of therapeutic proteins is lyophilization. The 
lyophilization process is a trusted aseptic process 
operation meeting the product sterility assurance 
requirement without the stress of terminal 
sterilization (19). 
This work focuses on examination of ready-to-
label lyophilized rituximab immune conjugates 
in order to increase the stability. In the search 
for a radioimmunoconjugate of higher efficiency 
and lower toxicity, obtained preparations of 
two bifunctional chelating agents (BFCA), 
p-SCN-Bn-DOTA and p-SCN-Bn-DTPA 
where compared. While preparations of these 
or other derivatives of DOTA and DTPA radio 
immune conjugates has been reported, chemical 
characteristics, stability and biodistribution of 
the prepared radioimmunoconjugates have not 
been explained in details. The main goal of this 
investigation was chemical characterization 
of the obtained immune complexes, analysis 
of identity, purity and post-lyophilization 
modifications.
Experimental
Materials and Methods
Materials
p-SCN-Bn-DOTA [2-(4-isothiocyanatobenzyl)-
1,4,7,10-tetraazacyclododecane-tetraacetic acid] and 
p-SCN-Bn-DTPA [2-(4-isothiocyanatobenzyl)-
diethylenetriaminepentaacetic acid] with 94% 
purity were obtained from Macrocyclics Inc. 
(NJ, USA). Rituximab was purified from a 
commercial pharmaceutical sample (Mabthera®), 
purchased from Roche Co, CA, USA, using 
ultrafiltration (Ultracel® - 30K, Millipore, 
Ireland) for concentration and buffer exchange 
to sterile 0.1 M PBS, pH 8.0. 
Matrix-Assisted Laser Desorption Ionization 
time-of-flight (MALDI-TOF) mass spectrometry 
was performed with Voyager-De MALDI-TOF 
(Applied Biosystems). Sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) 
was performed on the mini-gel system (GE 
Healthcare/Amersham Biosciences). Fourier 
Transform Infrared (FT-IR) spectroscopy was 
applied for determination of protein secondary 
structure. FT-IR-Spectrometer, PARAGON 
1000 (Perkin Elmer) was used for recording IR 
spectra of investigated compounds. 
Conjugation of Rituximab to p-SCN-Bn-
DOTA and p-SCN-Bn-DTPA 
BFCA’s were dissolved in 0.1 M PBS (pH 8.0) 
to final concentration of 10 mg/mL. Calculated 
amounts of BFCA required to give a 20-fold 
molar excess over the amount of Rituximab (10 
mg/mL) were added to the purified monoclonal 
antibody in 0.1 M PBS (pH 8.0). The mixture 
was incubated overnight, at 4 °C with gentle 
shaking. Purification of the conjugates was 
made with ultrafiltration (Ultracel® - 30K, 
Millipore, Ireland), by washing the immune 
conjugates with 0.05 M ammonium acetate, pH 
7.0, until the absorbance in the ultrafiltrate set 
at 280 nm was nearly zero (meaning that there 
is no unbound chelating agent in the immune 
conjugate solution).
Lyophilization Process
The lyophilization was performed using 
Labconco Free Zone Stoppering Tray Dryer, 
(USA) using protocol described by Park et al. in 
2013 (20), modified to our experience. Briefly, 
the liquid immunoconjugates were filled in 10 
mL type I glass tubing vials using a fill volume of 
1 mL loaded in the freeze-dryer. The temperature 
was decreased to -40 °C at 0.40 °C/min and held 
for 3 h, increased to -15 °C, to allow complete 
crystallization, thus completing the freezing step 
in 10 h. The primary drying was performed at 
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temperature of -10 °C and the secondary drying 
at shelf temperature 25 °C. Upon finishing the 
process, the vials were stoppered and kept at 
4 °C until analysis.
Protein Integrity Test Using SDS-PAGE
SDS-PAGE was performed according to 
Laemmli protocol (21). About 5 µL of sample 
was mixed with 10 µL of sample buffer. 
The samples were boiled for 5 min at 95 °C. 
Approximately 5 µL of each preparation was 
applied per lane in 12% bisacrylamide under 
reducing conditions. Coomassie staining 
(Coomassie Brilliant Blue R-250, Sigma) was 
performed according to the manufacturer’s 
instructions. All chemicals used were reagent 
and HPLC grade. As molecular marker Low 
molecular weight marker (Amersham GE 
Healthcare) was used.
Protein Characterisation by MALDI-TOF MS
Both characterization of the conjugates 
and determination of the average number of 
BFCA attached to each antibody molecule is 
performed by MALDI-TOF mass spectrometry. 
A representative procedure can be outlined 
as follows: A volume (10 µL) of the solution 
of the conjugated BFCA’s was diluted (1:10) 
with a matrix solution of 3,5-dimethoxy-4-
hydroxycinnamic acid [10 mg/mL dissolved 
in a mixture of acetonitrile (50%)/TFA (1%), 
Sigma] to a concentration of about 10 pmol/
μL. An aliquot (1-2 μL) of the final solution 
was applied to the sample target prior to 
insertion into the high vacuum chamber of a 
mass spectrometer. Operational conditions 
for the MALDI-TOF apparatus were set as 
follows: mode of operation, linear; polarity, 
positive; acceleration voltage, 20000 V; delayed 
extraction time, 100 nsec; aquisition mass range, 
140000-170000 Da.
FT-IR Spectroscopy 
The lyophilized samples were used for FT-
IR study. The spectral range was 2000–500 
cm-1 and the samples were scanned with ATR 
(Attenuated Total Reflectance) technique three 
times to minimize the influence of spotting 
variance. Spectra were acquired at a resolution 
of 4 cm-1 and 128 spectra were co-added to 
improve  the signal-to-noise ratio. After spectral 
acquisition, data were exported and analyzed 
using the Grams_32 software.
Results and Discussion
 
The preparation of protein therapeutics as 
lyophilized (freeze-dried) products is often 
essential to obtain the mandatory stability during 
shipping and long-term storage.
Because of its protein nature, rituximab 
may go through a variety of chemical and 
physical degradation processes (22). Chemical 
instability, concerns covalent bond modifications 
(asparagine deamidation, oxidation or disulfide 
bond rearrangement) (23), while physical 
instability mostly concerns low energy bonds 
(hydrogen bonds), and includes adsorption on to 
surfaces, unfolding and aggregation (24). 
As it is an important challenge to access the 
stability of monoclonal antibodies as a part from 
biotechnology-derived radiopharmaceuticals, 
we conducted a study to evaluate the 
physicochemical stability of two ready-to-
label lyophilized rituximab immunoconjugates. 
Various protein characterization methods were 
used to determine changes in physicochemical 
properties of rituximab conjugates after 
lyophilization.
In our study, as chelator molecules, 
derivatives of DOTA and DTPA were employed, 
and their structures are shown in Figure 1.
In order to demonstrate the integrity of 
the protein and purity after conjugation and 
lyophilization, SDS-PAGE was performed 
using 12% bisacrylamide gel. The loaded 
samples were Rituximab (1 mg/mL, commercial 
sample), conjugated p-SCN-Bn-DOTA, p-SCN-
Bn-DTPA in liquid form and reconstituted 
lyophilized formulation, both in concentration 
of 1 mg/mL Figure 2. shows the SDS-PAGE 
patterns for BFCA conjugates, compared to 
unconjugated rituximab as control sample.
All BFCA-rituximab conjugates (before 
and after lyophilization) were resolved in two 
distinct Mw species which migrated in two 
bands (upper band at ~50 kDa and lower band 
at ~25 kDa) confirming the migration behavior 
typical for IgG antibodies which are composed 
of two identical subunits each composed by two 
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polypeptide chains: two heavy and two light 
chains, linked via disulfide bonds. The obtained 
fragments correspond to molecular masses 
of rituximab heavy and light chain given in 
theliterature  (25). 
As it is shown in Figure 2. the reducing 
SDS-PAGE patterns for rituximab, and BFCA-
rituximab immunoconjugates were with very 
similar intensity. The reducing SDS-PAGE 
results, compared to the result of commercially 
available rituximab sample, showed no clear 
indication for antibody degradation. Similar 
results were obtained for one month integrity test 
on stored BFCA-rituximab immunoconjugates 
(results not shown). 
One of the most important quality attributes 
of the immuneconjugates is the average number 
of chelator molecules that are conjugated 
because this deter mines the drug distribution and 
the amount of “payload” that can be delivered to 
the tumor cell and can directly affect both safety 
and efficacy. 
The characterization of the conjugates and 
the determination of the average number of 
BFCA attached to each antibody molecule were 
performed by MALDI-TOF MS, as shown on 
Figure 3. and 4. respectively for p-SCN-Bn-
DOTA-rituximab conjugate and  p-SCN-Bn-
DTPA-rituximab conjugate.
This technique is a rapid and sensitive 
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Figure 1: Structure of used BFCAs: a) p-SCN-Bn-DOTA, b) p-SCN-Bn-DTPA. 
Figure 2: Reducing SDS-PAGE lane patterns for rituximab (1) (1 mg/mL), DOTA-rituximab 
conjugate, before lyophilization (2), DTPA-rituximab conjugate, before lyophilization (3),
DOTA-rituximab conjugate, after lyophilization (4) and DTPA-rituximab conjugate, after 
lyophilization (5); M is molecular marker; 
 
N
NN
N
COOH
COOH
COOH
COOH
NCS
         
N N N COOH
COOHHOOC
HOOC
HOOC
SCN
a)                                                b) 
Figure 1: Structure of used BFCAs: a) p-SCN-Bn-DOTA, b) p-SCN-Bn-DTPA. 
Figure 2: Reducing SDS-PAGE lane patterns for rituximab (1) (1 mg/mL), DOTA-rituximab 
conjugate, before lyophilization (2), DTPA-rituximab conjugate, before lyophilization (3),
DOTA-rituximab conjugate, after lyophilization (4) and DTPA-rituximab conjugate, after 
lyophilization (5); M is molecular marker; 
 
Figure 1. Structure of used BFCAs: a) p-SCN-Bn-DOTA, b) p-SCN-Bn-DTPA.
N
NN
N
COOH
COOH
COOH
COOH
NCS
         
N N N COOH
COOHHOOC
HOOC
HOOC
SCN
a)                                                b) 
Figure 1: Structure of used BFCAs: a) p-S N-Bn-DOTA, b) p-SCN-Bn-DTPA. 
Figure 2: Reducing SDS-PAGE lane patterns for ri uximab (1) (1 mg/mL), DOTA-rituximab 
conjugate, before lyophilization (2), DTPA-rituximab conjugate, before lyophilization (3),
DOTA-rituximab conjugate, after lyophilization (4) and DTPA-rituximab conjugate, after 
lyophilization (5); M is molecular marker; 
 
Figure 2: Reducing SDS-PAGE lane patterns for rituximab (1) (1 mg/mL), p-SCN-Bn-DOTA-rituximab conjugate, before lyophilization 
(2), p-SCN-Bn-DTPA-rituximab  conjugate, before lyophilization (3), DOTA-rituximab conjugate, after lyophilization (4) and p-SCN-
Bn-DTPA-rituximab
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analytical tool for peptide and protein 
characterization. Used in a variety of modes, 
MALDI-MS provides information such as the 
molecular weight of an intact protein, peptide 
mass mapping from a tryptic digest, and peptide 
sequencing. MALDI-TOF MS as a “soft” 
ionization technique is suitable for thermolabile, 
nonvolatile compounds, especially those of 
high molecular mass and is used successfully 
in biochemical and biotechnological areas for 
the analysis of therapeutic proteins, peptides, 
glycoproteins, complex carbohydrates and 
oligonucleotides. One of the first reports of 
mass spectroscopic characterization of immuno 
conjugates describes use of a UV MALDI-
TOF instrument (26, 27), where mass spectra 
of intact antibodies conjugated through lysine 
residues or through antibody carbohydrates with 
chelating agents (DTPA, macro cycle 12N4) or 
with drugs (calicheamicin, methotrexate, mito-
xantrone) were compared with the corresponding 
unconjugated antibodies.
MALDI-TOF results for P-SCN-Bn-DOTA-
rituximab conjugate, after lyophilization 
(shown on Figure 3), revealed the presence 
of two major peaks corresponding to a Mw of 
146491 Da (unconjugated mAb), and 149873 
Da (conjugated mAb) which corresponds to an 
average of 6.1 groups of p-SCN-Bn-DOTA per 
molecule of rituximab. No structural changes 
in terms of appearance of additional peaks were 
observed. 
MALDI-TOF results for  p-SCN-Bn-DTPA-
rituximab conjugate, after lyophilization (shown 
on Figure 4), revealed the presence of two 
major peaks also, corresponding to a Mw of 
Figure 3: MALDI-TOF results for DOTA-rituximab conjugate. 
Figure 4: MALDI-TOF results for DTPA-rituximab conjugate. 
Figure 3: MALDI-TOF results for DOTA-rituximab conjugate. 
Figure 4: MALDI-TOF results for DTPA-rituximab conjugate. 
Figure 3 . MALDI-T F resul s for DOTA-rituximab conjugate.
Figure 4: MALDI-TOF results for  p-SCN-Bn-DTPA-rituximab conjugate.
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146477 Da (unconjugated mAb), and 151246 
Da (conjugated mAb) which corresponds to an 
average of 8.8 groups of p-SCN-Bn-DTPA per 
molecule of rituximab.
According to literature data (9), 4.25 ± 
1.04 DOTA-SCN molecules attached to each 
antibody molecule are found to be sufficient for 
prompt subsequent labelling with radioisotope. 
This is result for investigated molar ratio 1:50 
(antibody:chelator). Our results of average of 
6.1 groups of p-SCN-Bn-DOTA and 8.8 groups 
of p-SCN-Bn-DTPA per molecule of rituximab, 
pointed that this number can be increased using 
different molar ratios for conjugation, as 1:20 
in this case. 
In another study, up to five DOTA molecules 
were conjugated to MORAb-003, with no 
apparent loss of immunoreactivity (28). 
Highly DOTA-substituted anti-tumor antibody 
leads to the formation of immunoconjugates 
with high specific activity and excellent in-
vivo behavior which is a valuable option for 
radioimmunotherapy and potentially antibody-
drug conjugates (29).
Infrared (IR) spectroscopy appears as 
valuable method for monitoring protein 
denaturation upon lyophilization (30), although 
other methods have also been used such as mass 
spectroscopy (31), and Raman spectroscopy 
(32). In this study, the secondary structure of 
the protein in dried state was monitored using 
FT-IR spectroscopy. The IR spectra of the 
investigated compounds were recorded in the 
region 500-2000 cm-1 and compared to the IR 
spectra recorded for unconjugated rituximab. 
The results are shown on Figure 5. 
Each type of secondary structure (i.e. α-helix, 
β-sheet, β-turn and disordered) gives rise to 
different C=O stretching band frequencies. Most 
structural information is obtained by analysis 
of the conformationally-sensitive amide I band, 
which is located between 1600 and 1700 cm-1 
(33, 34). According to previous investigations 
(33), a strong amide II band is observed at 
1540–1550 cm-1 and a weaker shoulder at 
1510–1525 cm-1. Antibody molecules are 
predominantly made of β-sheet (47%), 7% of 
α-helices, and the remaining percentage, of 
turns and coils (35). For all samples, namely, 
rituximab (1619; 1636; 1687 cm-1), P-SCN-Bn-
DOTA-rituximab (1638; 1656; 1678 cm-1), and 
DTPA-rituximab (1636; 1656; 1679 cm-1) in 
the amide I region, in the recorded IR spectra 
(Figure 5.), we detected predominantly bands 
characteristic for β-structure. 
These findings are in accordance with 
literature data (33, 34). No modification in 
the obtained IR spectra of conjugates was 
observed, and in correlation with stability 
as indicated by results obtained by SDS-
PAGE, the results revealed maintenance of 
the antibody native structure. Based on these 
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Figure 5: IR spectra of rituximab, DOTA-rituximab and DTPA-rituximab (after 
lyophilization). 
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results, we can conclude that conjugation 
and lyophilization process did not affected 
structure properties and caused no post-
lyophilization modifications justifying the use 
of these formulations in further investigations 
for subsequent radionuclide labeling. The 
assignment of immunoconjugates (monoclonal 
antibodies with preserved secondary β-sheet 
structure of rituximab) as well as detailed 
analysis of characteristic bands shifts in 
rituximab vibrational spectra (depending on the 
presence of different chelators) is in progress.
Conclusions
Our results demonstrate that after 
lyophilization, diluted (1 mg/mL in saline) 
rituximab immunoconjugates remain stable. 
Indeed, no modification of its chemical, physical 
and structural characteristics and no aggregation 
were observed. Further experiments are needed 
in order to demonstrate their biological and 
pharmacological properties. These results 
indicate that the time frame for the practical 
use of rituximab immune conjugates can be 
safely extended using lyophilization, allowing, 
for example, safe and longer storage. Our 
results also support the possibility of preparing 
standardized batches of “ready-to-label” 
rituximab immuno conjugates, following good 
manufacturing procedures. This can be a good 
base for conducting further experiments with 
radiolabeled formulations in order to develop a 
new promising radiopharmaceutical for therapy 
of NHL.
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